Fig. 5. Blocking integrin ß1 or Src activity inhibits cell elongation and invasion. (A) BE cells were plated on Matrigel and treated with either blocking ß1 integrin antibody (4B4; 10 µg/ml), Src inhibitor (PP2, 10 µM), Src inhibitor control (PP3, 10 µM) or an inhibitor of EGF receptor (AG1487, 10 µM) for 8 hours. Elongation profiles were then analysed by phase contrast microscopy. Representative images are shown and average percentage cell elongation, which was analysed from 20 independent cell images, is reported with standard deviations; Control 161.2±17.8%, anti-ß1 3.6±8.9%, PP3 153.3±24.7%, PP2 11.8±12.3%, AG1827 155.8±21.9%. (B) HUVECs were plated on Matrigel and treated as in part A. Elongation profiles were analysed by fluorescent microscopy. (C) Serum-starved cells treated as for part A were plated onto Matrigel-coated Transwell chambers and invasion through the filter and into the matrix towards serum (10%) was analysed by microscopy after 48 hours. Results are representative of five independent experiments with the average percentage (number) of invading cells compared with control (untreated, 100%) sample displayed with standard deviations: 1, control; 2, anti-ß1; 3, PP2; 4, PP3.